With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines

2.

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says

3.

Pollution exposure may affect lung cancer in women who have never smoked

4.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

5.

Dense breasts: What it means and what women can do about screening


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot